Terms: = Prostate cancer AND SPEN, Q96T58, 23013, ENSG00000065526, SHARP, RP1-134O19_1, MINT, KIAA0929 AND Staging
1840 results:
1. Risk factor analysis and optimal cutoff value selection of PSAD for diagnosing clinically significant prostate cancer in patients with negative mpMRI: results from a high-volume center in Southeast China.
Lin S; Jiang W; Ding J; Hao S; Chen H; Xie L; Zheng X
World J Surg Oncol; 2024 May; 22(1):140. PubMed ID: 38802859
[TBL] [Abstract] [Full Text] [Related]
2. [Stage at diagnosis of prostate cancer in an institutional hospital. Review and comparison of national and international data].
Pauchard F; Kramer F; Kirmayr M; Escobar M
Rev Med Chil; 2023 Jun; 151(6):711-716. PubMed ID: 38801379
[TBL] [Abstract] [Full Text] [Related]
3. IL-38 promotes the development of prostate cancer.
Wu H; Yang J; Yuan L; Tan Z; Zhang X; Hambly BD; Bao S; Tao K
Front Immunol; 2024; 15():1384416. PubMed ID: 38779687
[TBL] [Abstract] [Full Text] [Related]
4. Low-Density Lipoprotein Cholesterol and prostate cancer: A Retrospective Study.
Hu P; Cheng R; Chen G; Hu X; Shen Y
Arch Esp Urol; 2024 Apr; 77(3):229-234. PubMed ID: 38715162
[TBL] [Abstract] [Full Text] [Related]
5. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract] [Full Text] [Related]
6. Optimizing PSMA scintigraphy for resource limited settings - a retrospective comparative study.
Kolade OU; Brink A; Ayeni AO; More S; Holness J
Cancer Imaging; 2024 Apr; 24(1):46. PubMed ID: 38556864
[TBL] [Abstract] [Full Text] [Related]
7. Extended pelvic lymph node dissection in robot-assisted radical prostatectomy is an independent risk factor for major complications.
Baas DJH; de Baaij JMS; Sedelaar JPM; Hoekstra RJ; Vrijhof HJEJ; Somford DM; van Basten JA
J Robot Surg; 2024 Mar; 18(1):140. PubMed ID: 38554195
[TBL] [Abstract] [Full Text] [Related]
8. Extended pelvic lymph node dissection during robotic prostatectomy: antegrade versus retrograde technique.
Albo G; Gallioli A; Ripa F; De Lorenzis E; Boeri L; Bebi C; Rocchini L; Longo F; Zanetti SP; Turetti M; Piccoli M; Montanari E
BMC Urol; 2024 Mar; 24(1):64. PubMed ID: 38515053
[TBL] [Abstract] [Full Text] [Related]
9. Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer.
Lundberg F; Robinson D; Bratt O; Fallara G; Lambe M; Johansson ALV
Acta Oncol; 2024 Mar; 63():95-104. PubMed ID: 38505996
[TBL] [Abstract] [Full Text] [Related]
10. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive prostate cancer and Survival.
Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
[TBL] [Abstract] [Full Text] [Related]
11. Development of a prognostic model for long-term survival of young patients with bladder cancer: a retrospective analysis of the SEER Database.
Guo L; Liu L; Liu Y; Yang T; Wang G; Liu J; Li S; Cai J
BMJ Open; 2024 Mar; 14(3):e080092. PubMed ID: 38458812
[TBL] [Abstract] [Full Text] [Related]
12. [
Li B; Ding X; Duan L; Shi J; Tang M; Zhang J; Zhao Z; Wu X; Gao Y
Front Endocrinol (Lausanne); 2024; 15():1326858. PubMed ID: 38449842
[TBL] [Abstract] [Full Text] [Related]
13. Predictive accuracy of boosted regression model in estimating risk of venous thromboembolism following minimally invasive radical surgery in pharmacological prophylaxis-naïve men with prostate cancer.
Leong CH; Ranjan SR; Javed A; Alsaedi BSO; Nabi G
World J Surg Oncol; 2024 Feb; 22(1):67. PubMed ID: 38395873
[TBL] [Abstract] [Full Text] [Related]
14. Bone marrow metastasis in nonhematological malignancies: A study from tertiary care center.
Singh A; Rawat S; Kushwaha R; Jain M; Verma SP; Verma N; Singh US
Ann Afr Med; 2024; 23(1):91-99. PubMed ID: 38358178
[TBL] [Abstract] [Full Text] [Related]
15. Analytical performance validation of aPROMISE platform for prostate tumor burden, index and dominant tumor assessment with 18F-DCFPyL PET/CT. A pilot study.
García Vicente AM; Lucas Lucas C; Pérez-Beteta J; Borrelli P; García Zoghby L; Amo-Salas M; Soriano Castrejón ÁM
Sci Rep; 2024 Feb; 14(1):3001. PubMed ID: 38321201
[TBL] [Abstract] [Full Text] [Related]
16. Intraductal prostate cancer Affinity for Lymphatic-Predominant Metastases Through
Bernardino R; Sayyid RK; Lajkosz K; Al-Daqqaq Z; Tiwari R; Cockburn J; Leão R; Metser U; Berlin A; van der Kwast T; Fleshner NE
J Urol; 2024 Apr; 211(4):586-593. PubMed ID: 38299501
[TBL] [Abstract] [Full Text] [Related]
17. The Ability of the STAR-CAP staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial Treatment of M0 prostate cancer.
Sung D; Schmidt B; Tward JD
Clin Genitourin Cancer; 2024 Apr; 22(2):426-433.e5. PubMed ID: 38290900
[TBL] [Abstract] [Full Text] [Related]
18. Combined whole-body dynamic and static PET/CT with low-dose [
Sachpekidis C; Pan L; Groezinger M; Strauss DS; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2137-2150. PubMed ID: 38286936
[TBL] [Abstract] [Full Text] [Related]
19. Contribution of 68 Ga-DOTA-FAPI-04 PET/CT to prostate cancer Imaging : Complementary Role in PSMA-Negative Cases.
Ergül N; Çermik TF; Alçın G; Arslan E; Erol Fenercioğlu Ö; Beyhan E; Şahin R; Baloğlu MC; Baykal Koca S; Türkay R; Yücetaş U
Clin Nucl Med; 2024 Mar; 49(3):e105-e110. PubMed ID: 38271254
[TBL] [Abstract] [Full Text] [Related]
20. prostate cancer Risk Stratification by Simple Scoring of the Current pT3 Lesions: A Proposal for a New Pathologic T-staging System.
Miyamoto H; Teramoto Y; Numbere N; Wang Y; Joseph JV
Mod Pathol; 2024 Mar; 37(3):100429. PubMed ID: 38266919
[TBL] [Abstract] [Full Text] [Related]
[Next]